Evolutionary karyotypic theory of cancer versus conventional cancer gene mutation theory

Biopolymers and Cell

Volumn 28, Issue 4, 2012, Pages 267-280

  Stepanenko, A A ^a   Kavsana, V M ^a  

^a INSTITUTE OF MOLECULAR BIOLOGY AND GENETICS   (Ukraine)

Author keywords

Cancer gene; Chromosome instability; Drug resistance; Intratumor heterogeneity; Karyotype; Tumor evolution

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IMATINIB; MULTIDRUG RESISTANCE PROTEIN; NILOTINIB; NOCODAZOLE; PACLITAXEL; PACLITAXEL DERIVATIVE; RAPAMYCIN; TAMOXIFEN;

ANEUPLOIDY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CANDIDA ALBICANS; CARCINOGENESIS; CARCINOGENICITY; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATION; DNA DAMAGE; DRUG METABOLISM; EPIGENETICS; ESCHERICHIA COLI; EXOME; GENE AMPLIFICATION; GENE DOSAGE; GENE MUTATION; GENE SEQUENCE; GENETIC CODE; GENETIC HETEROGENEITY; HUMAN; KARYOTYPING; LEISHMANIA; NONHUMAN; OVARY CANCER; PROSTATE CANCER; SACCHAROMYCES CEREVISIAE; SOMATIC MUTATION; TUMOR GENE; TUMOR GROWTH;

EID: 84864396760     PISSN: 02337657     EISSN: 19936842     Source Type: Journal    
DOI: 10.7124/bc.000059     Document Type: Article

References (242)

1. Leroi A. M., Koufopanou V., Burt A. Cancer selection. Nat. Rev. Cancer. 2003. 3, N 3. P. 226-231.
2. Caulin A. F., Maley C. C. Peto’s Paradox: evolution’s prescription for cancer prevention. Trends Ecol. Evol. 2011. 26, N 4. P. 175-182.
3. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011. 61, N 2. P. 69-90.
4. Bourke M. G., Salwa S., Harrington K. J., Kucharczyk M. J., Forde P. F., de Kruijf M., Soden D., Tangney M., Collins J. K., O’Sullivan G. C. The emerging role of viruses in the treatment of solid tumours. Cancer Treat. Rev. 2011. 37, N 8. P. 618-632.
5. Reeder-Hayes K. E., Carey L. A., Sikov W. M. Clinical trials in triple negative breast cancer. Breast Dis. 2010. 32, N 1-2. P. 123-136.
6. Torti D., Trusolino L. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol. Med. 2011. 3, N 11. P. 623-636.
7. Plate J. Clinical trials of vaccines for immunotherapy in pancreatic cancer. Expert Rev. Vaccines. 2011. 10, N 6. P. 825-836.
8. Brookman-May S., Burger M., Wieland W. F., Rossler W., May M., Denzinger S. Vaccination therapy in renal cell carcinoma: current position and future options in metastatic and localized disease. Expert Rev. Vaccines. 2011. 10, N 6. P. 837-852.
9. Leffers N., Daemen T., Boezen H. M., Melief K. J., Nijman H. W. Vaccine-based clinical trials in ovarian cancer. Expert Rev. Vaccines. 2011. 10, N 6. P. 775-784.
10. Santarpia M., Altavilla G., Salazar M. F., Magri I., Pettineo G., Benecchi S., Rosell R. Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive. Expert Rev. Respir. Med. 2011. 5, N 3. P. 413-424.
11. Yoong J., Michael M., Leong T. Targeted therapies for gastric cancer: current status. Drugs. 2011. 71, N 11. P. 1367-1384.
12. Blank C. U., Hooijkaas A. I., Haanen J. B., Schumacher T. N. Combination of targeted therapy and immunotherapy in melanoma. Cancer Immunol. Immunother. 2011. 60, N 10. P. 1359-1371.
13. Coppin C., Kollmannsberger C., Le L., Porzsolt F., Wilt T. J. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int. 2011. 108, N 10. P. 1556-1563.
14. Banerjee S., Kaye S. The role of targeted therapy in ovarian cancer. Eur. J. Cancer. 2011. 47, Suppl 3. S116-130.
15. Higgins M. J., Baselga J. Targeted therapies for breast cancer. J. Clin. Invest. 2011. 121, N 10. P. 3797-3803.
16. Pujade-Lauraine E., Alexandre J. Update of randomized trials in recurrent disease. Ann. Oncol. 2011. 22, Suppl. 8. P. viii61-viii64.
17. Leung M., Rosen D., Fields S., Cesano A., Budman D. R. Poly (ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality. Mol. Med. 2011. 17, N 7-8. P. 854-862.
18. Jansen M. H., van Vuurden D. G., Vandertop W. P., Kaspers G. J. Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. Cancer Treat. Rev. 2012. 38, N 1. P. 27-35.
19. Perez-Lorenzo R., Zheng B. Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma. Biosci. Rep. 2012. 32, N 1. P. 25-33.
20. Singer E. A., Gupta G. N., Srinivasan R. Targeted therapeutic strategies for the management of renal cell carcinoma. Curr. Opin. Oncol. 2012. 24, N 3. P. 284-290.
21. Mackey J. R., Kerbel R. S., Gelmon K. A., McLeod D. M., Chia S. K., Rayson D., Verma S., Collins L. L., Paterson A. H., Robidoux A., Pritchard K. I. Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials. Cancer Treat. Rev. 2012. 38, N 6. P. 637-688
22. Chan S. L., Yeo W. Targeted therapy of hepatocellular carcinoma: present and future. J. Gastroenterol. Hepatol. 2012. 27, N 5. P. 862-872.
23. Duesberg P., Fabarius A., Hehlmann R. Aneuploidy, the primary cause of the multilateral genomic instability of neoplastic and preneoplastic cells. IUBMB Life. 2004. 56, N 2. P. 65-81.
24. Duesberg P., Li R., Fabarius A., Hehlmann R. The chromosomal basis of cancer. Cell Oncol. 2005. 27, N 5-6. P. 293-318.
25. Duesberg P., Li R., Fabarius A., Hehlmann R. Aneuploidy and cancer: from correlation to causation. Contrib. Microbiol. 2006. 13. P. 16-44.
26. Heng H. H., Stevens J. B., Liu G., Bremer S. W., Ye K. J., Reddy P. V., Wu G. S., Wang Y. A., Tainsky M. A., Ye C. J. Stochastic cancer progression driven by non-clonal chromosome aberrations. J. Cell. Physiol. 2006. 208, N 2. P. 461-472.
27. Heng H. H., Bremer S. W., Stevens J. B., Ye K. J., Liu G., Ye C. J. Genetic and epigenetic heterogeneity in cancer: a genome-centric perspective. J. Cell. Physiol. 2009. 220, N 3. P. 538-547.
28. Heng H. H., Stevens J. B., Bremer S. W., Ye K. J., Liu G., Ye C. J. The evolutionary mechanism of cancer. J. Cell. Biochem. 2010. 109, N 6. P. 1072-1084.
29. Fox E. J., Salk J. J., Loeb L. A. Cancer genome sequencing an interim analysis. Cancer Res. 2009. 69, N 12. P. 4948-4950.
30. Ciccarelli F. D. The (r)evolution of cancer genetics. BMC Biol. 2010. 8. P. 74
31. Syed A. S., D’Antonio M., Ciccarelli F. D. Network of Cancer Genes: a web resource to analyze duplicability, orthology and network properties of cancer genes. Nucleic Acids Res. 2010. 38. D670-675.
32. Bessarabova M., Pustovalova O., Shi W., Serebriyskaya T., Ishkin A., Polyak K., Velculescu V. E., Nikolskaya T., Nikolsky Y. Functional synergies yet distinct modulators affected by genetic alterations in common human cancers. Cancer Res. 2011. 71, N 10. P. 3471-3481.
33. D’Antonio M., Pendino V., Sinha S., Ciccarelli F. D. Network of Cancer Genes (NCG 3.0): integration and analysis of genetic and network properties of cancer genes. Nucleic Acids Res. 2012. 40. D978-983.
34. Loeb L. A. Human cancers express mutator phenotypes: origin, consequences and targeting. Nat. Rev. Cancer. 2011. 11, N 6. P. 450-457.
35. Kan Z., Jaiswal B. S., Stinson J., Janakiraman V., Bhatt D., Stern H. M., Yue P., Haverty P. M., Bourgon R., Zheng J., Moorhead M., Chaudhuri S., Tomsho L. P., Peters B. A., Pujara K., Cordes S., Davis D. P., Carlton V. E., Yuan W., Li L., Wang W., Eigenbrot C., Kaminker J. S., Eberhard D. A., Waring P., Schuster S. C., Modrusan Z., Zhang Z., Stokoe D., de Sauvage F. J., Faham M., Seshagiri S. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010. 466, N 7308. P. 869-873.
36. Futreal P. A., Coin L., Marshall M., Down T., Hubbard T., Wooster R., Rahman N., Stratton M. R. A census of human cancer genes. Nat. Rev. Cancer. 2004. 4, N 3. P. 177-183.
37. Xu X., Hou Y., Yin X., Bao L., Tang A., Song L., Li F., Tsang S., Wu K., Wu H., He W., Zeng L., Xing M., Wu R., Jiang H., Liu X., Cao D., Guo G., Hu X., Gui Y., Li Z., Xie W., Sun X., Shi M., Cai Z., Wang B., Zhong M., Li J., Lu Z., Gu N., Zhang X., Goodman L., Bolund L., Wang J., Yang H., Kristiansen K., Dean M., Li Y., Wang J. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell. 2012. 148, N 5. P. 886-895.
38. Navin N., Kendall J., Troge J., Andrews P., Rodgers L., McIndoo J., Cook K., Stepansky A., Levy D., Esposito D., Muthuswamy L., Krasnitz A., McCombie W. R., Hicks J., Wigler M. Tumour evolution inferred by single-cell sequencing. Nature. 2011. 472, N 7341. P. 90-94.
39. Gerlinger M., Rowan A. J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., Varela I., Phillimore B., Begum S., McDonald N. Q., Butler A., Jones D., Raine K., Latimer C., Santos C. R., Nohadani M., Eklund A. C., Spencer-Dene B., Clark G., Pickering L., Stamp G., Gore M., Szallasi Z., Downward J., Futreal P. A., Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012. 366, N 10. P. 883- 892.
40. Knight S. J., Yau C., Clifford R., Timbs A. T., Akha E. S., Dreau H. M., Burns A., Ciria C., Oscier D. G., Pettitt A. R., Dutton S., Holmes C. C., Taylor J., Cazier J. B., Schuh A. Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia. Leukemia. 2012. doi: 10. 1038/leu.2012.13.
41. Braggio E., Kay N. E., Vanwier S., Tschumper R. C., Smoley S., Eckel-Passow J. E., Sassoon T., Barrett M., Van Dyke D. L., Byrd J. C., Jelinek D. F., Shanafelt T. D., Fonseca R. Longitudinal genome wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse. Leukemia. 2012. doi: 10.1038/leu.2012.14
42. Yachida S., Jones S., Bozic I., Antal T., Leary R., Fu B., Kamiyama M., Hruban R. H., Eshleman J. R., Nowak M. A., Velculescu V. E., Kinzler K. W., Vogelstein B., Iacobuzio-Donahue C. A. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010. 467, N 7319. P. 1114-1117.
43. Lindberg J., Klevebring D., Liu W., Neiman M., Xu J., Wiklund P., Wiklund F., Mills I. G., Egevad L., Gronberg H. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur. Urol. 2012. doi: 10.1016/j.bbr.2011.03.031.
44. Bartholdi M. F., Ray F. A., Cram L. S., Kraemer P. M. Karyotype instability of Chinese hamster cells during in vivo tumor progression. Somat. Cell. Mol. Genet. 1987. 13, N 1. P. 1-10.
45. Miura M., Miura Y., Padilla-Nash H. M., Molinolo A. A., Fu B., Patel V., Seo B. M., Sonoyama W., Zheng J. J., Baker C. C., Chen W., Ried T., Shi S. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells. 2006. 24, N 4. P. 1095-1103.
46. Ragel B. T., Couldwell W. T., Gillespie D. L., Wendland M. M., Whang K., Jensen R. L. A comparison of the cell lines used in meningioma research. Surg. Neurol. 2008. 70, N 3. P. 295-307.
47. Marella N. V., Malyavantham K. S., Wang J., Matsui S., Liang P., Berezney R. Cytogenetic and cDNA microarray expression analysis of MCF10 human breast cancer progression cell lines. Cancer Res. 2009. 69, N 14. P. 5946-5953.
48. Blum B., Benvenisty N. The tumorigenicity of diploid and aneuploid human pluripotent stem cells. Cell Cycle. 2009. 8, N 23. P. 3822-3830.
49. Sotillo R., Schvartzman J. M., Socci N. D., Benezra R. Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal. Nature. 2010. 464, N 7287. P. 436-440.
50. Zitzelsberger H., Engert D., Walch A., Kulka U., Aubele M., Hofler H., Bauchinger M., Werner M. Chromosomal changes during development and progression of prostate adenocarcinomas. Br. J. Cancer. 2001. 84, N 2. P. 202-208.
51. Veltman J. A., van Weert I., Aubele M., Bot F. J., Ramaekers F. C., Manni J. J., Hopman A. H. Specific steps in aneuploidization correlate with loss of heterozygosity of 9p21, 17p13 and 18q21 in the progression of pre-malignant laryngeal lesions. Int. J. Cancer. 2001. 91, N 2. P. 193-199.
52. Aubele M., Auer G., Braselmann H., Nahrig J., Zitzelsberger H., Quintanilla-Martinez L., Smida J., Walch A., Hofler H., Werner M. Chromosomal imbalances are associated with metastasis-free survival in breast cancer patients. Anal. Cell. Pathol. 2002. 24, N 2-3. P. 77-87.
53. Pihan G. A., Wallace J., Zhou Y., Doxsey S. J. Centrosome abnormalities and chromosome instability occur together in preinvasive carcinomas. Cancer Res. 2003. 63, N 6. P. 1398- 1404.
54. Giehl M., Fabarius A., Frank O., Hochhaus A., Hafner M., Hehlmann R., Seifarth W. Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability. Leukemia. 2005. 19, N 7. P. 1192-1197.
55. Gorgoulis V. G., Vassiliou L. V., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., Venere M., Ditullio R. A. Jr., Kastrinakis N. G., Levy B., Kletsas D., Yoneta A., Herlyn M., Kittas C., Halazonetis T. D. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005. 434, N 7035. P. 907-913.
56. Jonkers Y. M., Claessen S. M., Perren A., Schmid S., Komminoth P., Verhofstad A. A., Hofland L. J., de Krijger R. R., Slootweg P. J., Ramaekers F. C., Speel E. J. Chromosomal instability predicts metastatic disease in patients with insulinomas. Endocr. Relat. Cancer. 2005. 12, N 2. P. 435-447.
57. Li X., Galipeau P. C., Sanchez C. A., Blount P. L., Maley C. C., Arnaudo J., Peiffer D. A., Pokholok D., Gunderson K. L., Reid B. J. Single nucleotide polymorphism-based genome-wide chromo- some copy change, loss of heterozygosity, and aneuploidy in Barrett’s esophagus neoplastic progression. Cancer. Prev. Res. (Phila). 2008. 1, N 6. P. 413-423.
58. Loncarevic I. F., Hering A., Posorski N., Linden T., Hoyer H., Bucsky P. Number of genomic imbalances correlates with the overall survival for adrenocortical cancer in childhood. Pediatr. Blood Cancer. 2008. 51, N 3. P. 356-362.
59. Paulson T. G., Maley C. C., Li X., Li H., Sanchez C. A., Chao D. L., Odze R. D., Vaughan T. L., Blount P. L., Reid B. J. Chromosomal instability and copy number alterations in Barrett’s esophagus and esophageal adenocarcinoma. Clin. Cancer Res. 2009. 15, N 10. P. 3305-3314.
60. Sheffer M., Bacolod M. D., Zuk O., Giardina S. F., Pincas H., Barany F., Paty P. B., Gerald W. L., Notterman D. A., Domany E. Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc. Natl Acad. Sci. USA. 2009. 106, N 17. P. 7131-7136.
61. Heilig C. E., Loffler H., Mahlknecht U., Janssen J. W., Ho A. D., Jauch A., Kramer A. Chromosomal instability correlates with poor outcome in patients with myelodysplastic syndromes irrespectively of the cytogenetic risk group. J. Cell Mol. Med. 2010. 14, N 4. P. 895-902.
62. Roylance R., Endesfelder D., Gorman P., Burrell R. A., Sander J., Tomlinson I., Hanby A. M., Speirs V., Richardson A. L., Birkbak N. J., Eklund A. C., Downward J., Kschischo M., Szallasi Z., Swanton C. Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer. Cancer Epidemiol. Biomarkers Prev. 2011. 20, N 10. P. 2183-2194.
63. Endesfelder D., McGranahan N., Birkbak N. J., Szallasi Z., Kschischo M., Graham T. A., Swanton C. A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables. Oncotarget. 2011. 2, N 7. P. 529- 537.
64. Smid M., Hoes M., Sieuwerts A. M., Sleijfer S., Zhang Y., Wang Y., Foekens J. A., Martens J. W. Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes. Breast Cancer Res. Treat. 2011. 128, N 1. P. 23-30.
65. Lagarde P., Perot G., Kauffmann A., Brulard C., Dapremont V., Hostein I., Neuville A., Wozniak A., Sciot R., Schoffski P., Aurias A., Coindre J. M., Debiec-Rychter M., Chibon F. Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. Clin. Cancer Res. 2011. 18, N 3. P. 826-838.
66. Bakhoum S. F., Danilova O. V., Kaur P., Levy N. B., Compton D. A. Chromosomal instability substantiates poor prognosis in patients with diffuse large B-cell lymphoma. Clin. Cancer Res. 2011. 17, N 24. P. 7704-7711.
67. Ylipaa A., Hunt K. K., Yang J., Lazar A. J., Torres K. E., Lev D. C., Nykter M., Pollock R. E., Trent J., Zhang W. Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors. Cancer. 2011. 117, N 2. P. 380-389.
68. Hata H., Matsuzaki H., Yoshida M., Sonoki T., Kuribayashi N., Nagasaki A., Kimura T., Harada N., Takatsuki K. Hyperdiploid myeloma cell as an indicator of poor prognosis and drug refractoriness. Int. J. Hematol. 1997. 66, N 2. P. 219-226.
69. Zwaan C. M., Kaspers G. J., Pieters R., Hahlen K., Huismans D. R., Zimmermann M., Harbott J., Slater R. M., Creutzig U., Veerman A. J. Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. Blood. 2002. 100, N 9. P. 3352-3360.
70. Weise A., Liehr T., Efferth T., Kuechler A., Gebhart E. Comparative M-FISH and CGH analyses in sensitive and drug-resistant human T-cell acute leukemia cell lines. Cytogenet. Genome Res. 2002. 98, N 2-3. P. 118-125.
71. Hattinger C. M., Reverter-Branchat G., Remondini D., Castellani G. C., Benini S., Pasello M., Manara M. C., Scotlandi K., Picci P., Serra M. Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques. Eur. J. Cell. Biol. 2003. 82, N 9. P. 483-493.
72. Akervall J., Guo X., Qian C. N., Schoumans J., Leeser B., Kort E., Cole A., Resau J., Bradford C., Carey T., Wennerberg J., Anderson H., Tennvall J., Teh B. T. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients. Clin. Cancer Res. 2004. 10, N 24. P. 8204-8213.
73. Duesberg P., Li R., Sachs R., Fabarius A., Upender M. B., Hehlmann R. Cancer drug resistance: the central role of the karyotype. Drug Resist. Updat. 2007. 10, N 1-2. P. 51-58.
74. Bouchet B. P., Bertholon J., Falette N., Audoynaud C., Lamblot C., Puisieux A., Galmarini C. M. Paclitaxel resistance in untransformed human mammary epithelial cells is associated with an aneuploidy-prone phenotype. Br. J. Cancer. 2007. 97, N 9. P. 1218-1224.
75. Davis E., Teng H., Bilican B., Parker M. I., Liu B., Carriera S., Goding C. R., Prince S. Ectopic Tbx2 expression results in polyploidy and cisplatin resistance. Oncogene. 2008. 27, N 7. P. 976-984.
76. Nicholson J. M., Duesberg P. On the karyotypic origin and evolution of cancer cells. Cancer Genet. Cytogenet. 2009. 194, N 2. P. 96-110.
77. Swanton C., Nicke B., Schuett M., Eklund A. C., Ng C., Li Q., Hardcastle T., Lee A., Roy R., East P., Kschischo M., Endesfelder D., Wylie P., Kim S. N., Chen J. G., Howell M., Ried T., Habermann J. K., Auer G., Brenton J. D., Szallasi Z., Downward J. Chromosomal instability determines taxane response. Proc. Natl Acad. Sci. USA. 2009. 106, N 21. P. 8671-8676.
78. McClelland S. E., Burrell R. A., Swanton C. Chromosomal instability: a composite phenotype that influences sensitivity to chemotherapy. Cell Cycle. 2009. 8, N 20. P. 3262-3266.
79. Gerlinger M., Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br. J. Cancer. 2010. 103, N 8. P. 1139-1143.
80. Klein A., Li N., Nicholson J. M., McCormack A. A., Graessmann A., Duesberg P. Transgenic oncogenes induce oncogene-independent cancers with individual karyotypes and phenotypes. Cancer Genet. Cytogenet. 2010. 200, N 2. P. 79-99.
81. Bacher U., Haferlach T., Alpermann T., Zenger M., Kroger N., Beelen D. W., Kern W., Schnittger S., Haferlach C. Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML. Biol. Blood Marrow Transplant. 2010. 16, N 12. P. 1649-1657.
82. Cooke S. L., Ng C. K., Melnyk N., Garcia M. J., Hardcastle T., Temple J., Langdon S., Huntsman D., Brenton J. D. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene. 2010. 29, N 35. P. 4905-4913.
83. Cooke S. L., Temple J., Macarthur S., Zahra M. A., Tan L. T., Crawford R. A., Ng C. K., Jimenez-Linan M., Sala E., Brenton J. D. Intra-tumour genetic heterogeneity and poor chemoradiotherapy response in cervical cancer. Br. J. Cancer. 2011. 104, N 2. P. 361-368.
84. Lee A. J., Endesfelder D., Rowan A. J., Walther A., Birkbak N. J., Futreal P. A., Downward J., Szallasi Z., Tomlinson I. P., Howell M., Kschischo M., Swanton C. Chromosomal instability confers intrinsic multidrug resistance. Cancer Res. 2011. 71, N 5. P. 1858-1870.
85. Morgan W. F., Murnane J. P. A role for genomic instability in cellular radioresistance?. Cancer Metastasis Rev. 1995. 14, N 1. P. 49-58.
86. Limoli C. L., Corcoran J. J., Jordan R., Morgan W. F., Schwartz J. L. A role for chromosomal instability in the development of and selection for radioresistant cell variants. Br. J. Cancer. 2001. 84, N 4. P. 489-492.
87. Fernandez L. A., Squatrito M., Northcott P., Awan A., Holland E. C., Taylor M. D., Nahle Z., Kenney A. M. Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation. Oncogene. 2011. 31, N 15. P. 1923-1937.
88. Birkbak N. J., Eklund A. C., Li Q., McClelland S. E., Endesfelder D., Tan P., Tan I. B., Richardson A. L., Szallasi Z., Swanton C. Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res. 2011. 71, N 10. P. 3447-3452.
89. Weaver B. A., Silk A. D., Cleveland D. W. Low rates of aneuploidy promote tumorigenesis while high rates of aneuploidy cause cell death and tumor suppression. Cell. Oncol. 2008. 30, N 5. P. 453.
90. Li L., McCormack A. A., Nicholson J. M., Fabarius A., Hehlmann R., Sachs R. K., Duesberg P. H. Cancer-causing karyotypes: chromosomal equilibria between destabilizing aneuploidy and stabilizing selection for oncogenic function. Cancer Genet. Cytogenet. 2009. 188, N 1. P. 1-25.
91. Weaver B. A., Cleveland D. W. The aneuploidy paradox in cell growth and tumorigenesis. Cancer Cell. 2008. 14, N 6. P. 431-433.
92. Weaver B. A., Cleveland D. W. The role of aneuploidy in promoting and suppressing tumors. J. Cell Biol. 2009. 185, N 6. P. 935-937.
93. Sheltzer J. M., Amon A. The aneuploidy paradox: costs and benefits of an incorrect karyotype. Trends Genet. 2011. 27, N 11. P. 446-453.
94. Nobusawa S., Lachuer J., Wierinckx A., Kim Y. H., Huang J., Legras C., Kleihues P., Ohgaki H. Intratumoral patterns of genomic imbalance in glioblastomas. Brain Pathol. 2010. 20, N 5. P. 936-944.
95. Almendro V., Fuster G. Heterogeneity of breast cancer: etiology and clinical relevance. Clin. Transl. Oncol. 2011. 13, N 11. P. 767-773.
96. Ruiz C., Lenkiewicz E., Evers L., Holley T., Robeson A., Kiefer J., Demeure M. J., Hollingsworth M. A., Shen M., Prunkard D., Rabinovitch P. S., Zellweger T., Mousses S., Trent J. M., Carpten J. D., Bubendorf L., Von Hoff D., Barrett M. T. Advancing a clinically relevant perspective of the clonal nature of cancer. Proc. Natl Acad. Sci. USA. 2011. 108, N 29. P. 12054-12059.
97. Siegmund K. D., Marjoram P., Tavare S., Shibata D. High DNA methylation pattern intratumoral diversity implies weak selection in many human colorectal cancers. PLoS One. 2011. 6, N 6. e21657.
98. Malek J. A., Mery E., Mahmoud Y. A., Al-Azwani E. K., Roger L., Huang R., Jouve E., Lis R., Thiery J. P., Querleu D., Rafii A. Copy number variation analysis of matched ovarian primary tumors and peritoneal metastasis. PLoS One. 2011. 6, N 12. e28561.
99. Snuderl M., Fazlollahi L., Le L. P., Nitta M., Zhelyazkova B. H., Davidson C. J., Akhavanfard S., Cahill D. P., Aldape K. D., Betensky R. A., Louis D. N., Iafrate A.J. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 2011. 20, N 6. P. 810-817.
100. Hogan L. E., Meyer J. A., Yang J., Wang J., Wong N., Yang W., Condos G., Hunger S. P., Raetz E., Saffery R., Relling M. V., Bhojwani D., Morrison D. J., Carroll W. L. Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood. 2011. 118, N 19. P. 5218-5226.
101. Buob D., Fauvel H., Buisine M. P., Truant S., Mariette C., Porchet N., Wacrenier A., Copin M. C., Leteurtre E. The complex intratumoral heterogeneity of colon cancer highlighted by laser microdissection. Dig. Dis. Sci. 2011. 57, N 5. P. 1271-1280.
102. Korshunov A., Remke M., Kool M., Hielscher T., Northcott P. A., Williamson D., Pfaff E., Witt H., Jones D. T., Ryzhova M., Cho Y. J., Wittmann A., Benner A., Weiss W. A., von Deimling A., Scheurlen W., Kulozik A. E., Clifford S. C., Peter Collins V., Westermann F., Taylor M. D., Lichter P., Pfister S. M. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathol. 2012. 123, N 4. P. 515-527.
103. Samuel N., Hudson T. J. The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat. Rev. Gastroenterol. Hepatol. 2011. 9, N 2. P. 77-87.
104. Anderson K., Lutz C., van Delft F. W., Bateman C. M., Guo Y., Colman S. M., Kempski H., Moorman A. V., Titley I., Swansbury J., Kearney L., Enver T., Greaves M. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature. 2011. 469, N 7330. P. 356-361.
105. Gunnarsson R., Mansouri L., Isaksson A., Goransson H., Cahill N., Jansson M., Rasmussen M., Lundin J., Norin S., Buhl A. M., Smedby K. E., Hjalgrim H., Karlsson K., Jurlander J., Geisler C., Juliusson G., Rosenquist R. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. Haematologica. 2011. 96, N 8. P. 1161-1169.
106. Kloosterman W. P., Hoogstraat M., Paling O., Tavakoli-Yaraki M., Renkens I., Vermaat J. S., van Roosmalen M. J., van Lieshout S., Nijman I. J., Roessingh W., van’t Slot R., van de Belt J., Guryev V., Koudijs M., Voest E., Cuppen E. Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancer. Genome Biol. 2011. 12, N 10. R103.
107. Russnes H. G., Navin N., Hicks J., Borresen-Dale A. L. Insight into the heterogeneity of breast cancer through next-generation sequencing. J. Clin. Invest. 2011. 121, N 10. P. 3810-3818.
108. Seol H., Lee H. J., Choi Y., Lee H. E., Kim Y. J., Kim J. H., Kang E., Kim S. W., Park S. Y. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod. Pathol. 2012. Doi: 10.1038/modpathol.2012.36.
109. Wu X., Northcott P. A., Dubuc A., Dupuy A. J., Shih D. J., Witt H., Croul S., Bouffet E., Fults D. W., Eberhart C. G., Garzia L., Van Meter T., Zagzag D., Jabado N., Schwartzentruber J., Majewski J., Scheetz T. E., Pfister S. M., Korshunov A., Li X. N., Scherer S. W., Cho Y. J., Akagi K., MacDonald T. J., Koster J., McCabe M. G., Sarver A. L., Collins V. P., Weiss W. A., Largaespada D. A., Collier L. S., Taylor M. D. Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature. 2012. 482, N 7386. P. 529-533.
110. Giuriato S., Felsher D. W. How cancers escape their oncogene habit. Cell Cycle. 2003. 2, N 4. P. 329-332.
111. Jonkers J., Berns A. Oncogene addiction: sometimes a temporary slavery. Cancer Cell. 2004. 6, N 6. P. 535-538.
112. Sharma S. V., Fischbach M. A., Haber D. A., Settleman J. «On-cogenic shock»: explaining oncogene addiction through differential signal attenuation. Clin. Cancer Res. 2006. 12, N 14, Pt 2. 4392s-4395s.
113. Sharma S. V., Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 2007. 21, N 24. P. 3214-3231.
114. Weinstein I. B., Joe A. Oncogene addiction. Cancer Res. 2008. 68, N 9. P. 3077-3080.
115. McCormick F. Cancer therapy based on oncogene addiction. J. Surg. Oncol. 2011. 103, N 6. P. 464-467.
116. Yan W., Zhang W., Jiang T. Oncogene addiction in gliomas: implications for molecular targeted therapy. J. Exp. Clin. Cancer Res. 2011. 30. P. 58.
117. Settleman J. Oncogene addiction. Curr. Biol. 2012. 22, N 2. R43-R44.
118. Fabarius A., Li R., Yerganian G., Hehlmann R., Duesberg P. Specific clones of spontaneously evolving karyotypes generate individuality of cancers. Cancer Genet. Cytogenet. 2008. 180, N 2. P. 89-99.
119. Duesberg P., Mandrioli D., McCormack A., Nicholson J. M. Is carcinogenesis a form of speciation?. Cell Cycle. 2011. 10, N 13. P. 2100-2114.
120. Duesberg P., Iacobuzio-Donahue C., Brosnan J. A., McCormack A., Mandrioli D., Chen L. Origin of metastases: Subspecies of cancers generated by intrinsic karyotypic variations. Cell Cycle. 2012. 11, N 6. P. 1151-1166.
121. Heng H. H., Liu G., Stevens J. B., Bremer S. W., Ye K. J., Ye C. J. Genetic and epigenetic heterogeneity in cancer: the ultimate challenge for drug therapy. Curr. Drug Targets. 2010. 11, N 10. P. 1304-1316.
122. Heng H. H., Stevens J. B., Bremer S. W., Liu G., Abdallah B. Y., Ye C. J. Evolutionary mechanisms and diversity in cancer. Adv. Cancer Res. 2011. 112. P. 217-253.
123. Merlo L. M., Pepper J. W., Reid B. J., Maley C. C. Cancer as an evolutionary and ecological process. Nat. Rev. Cancer. 2006. 6, N 12. P. 924-935.
124. Maley C. C., Galipeau P. C., Finley J. C., Wongsurawat V. J., Li X., Sanchez C. A., Paulson T. G., Blount P. L., Risques R. A., Rabinovitch P. S., Reid B. J. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet. 2006. 38, N 4. P. 468-473.
125. Shibata D. Clonal diversity in tumor progression. Nat. Genet. 2006. 38, N 4. P. 402-403.
126. Lyons J. G., Lobo E., Martorana A. M., Myerscough M. R. Clonal diversity in carcinomas: its implications for tumour progression and the contribution made to it by epithelial-mesenchymal transitions. Clin. Exp. Metastasis. 2008. 25, N 6. P. 665-677.
127. Klein C. A. Parallel progression of primary tumours and metastases. Nature Rev. Cancer. 2009. 9, N 4. P. 302-312.
128. Park S. Y., Gonen M., Kim H. J., Michor F., Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J. Clin. Invest. 2010. 120, N 2. P. 636-644.
129. Graham T. A., McDonald S. A. Genetic diversity during the development of Barrett’s oesophagus-associated adenocarcinoma: how, when and why?. Biochem. Soc. Trans. 2010. 38, N 2. P. 374-379.
130. Merlo L. M., Shah N. A., Li X., Blount P. L., Vaughan T. L., Reid B. J., Maley C. C. A comprehensive survey of clonal diversity measures in Barrett’s esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev. Res. (Phila). 2010. 3, N 11. P. 1388-1397.
131. Greaves M., Maley C. C. Clonal evolution in cancer. Nature. 2012. 481, N 7381. P. 306-313.
132. Davey P., Rauth A. M., Mason L., Addy L. Spontaneous phenotypic and karyotypic progression in the SV40 transfected cell line SVG during prolonged passage in vitro. J. Neurooncol. 1990. 8, N 1. P. 13-22.
133. Gao C., Furge K., Koeman J., Dykema K., Su Y., Cutler M. L., Werts A., Haak P., Vande Woude G. F. Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations. Proc. Natl Acad. Sci. USA. 2007. 104, N 21. P. 8995-9000.
134. Geyer F. C., Weigelt B., Natrajan R., Lambros M. B., de Biase D., Vatcheva R., Savage K., Mackay A., Ashworth A., Reis-Filho J. S. Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J. Pathol. 2010. 220, N 5. P. 562-573.
135. Kalisky T., Blainey P., Quake S. R. Genomic analysis at the single-cell level. Annu. Rev. Genet. 2011. 45. P. 431-445.
136. Bussey K. J., Chin K., Lababidi S., Reimers M., Reinhold W. C., Kuo W. L., Gwadry F., Ajay J., Kouros-Mehr H., Fridlyand J., Jain A., Collins C., Nishizuka S., Tonon G., Roschke A., Gehlhaus K., Kirsch I., Scudiero D. A., Gray J. W., Weinstein J. N. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol. Cancer Ther. 2006. 5, N 4. P. 853-867.
137. Yoshimoto T., Matsuura K., Karnan S., Tagawa H., Nakada C., Tanigawa M., Tsukamoto Y., Uchida T., Kashima K., Akizuki S., Takeuchi I., Sato F., Mimata H., Seto M., Moriyama M. High-resolution analysis of DNA copy number alterations and gene expression in renal clear cell carcinoma. J. Pathol. 2007. 213, N 4. P. 392-401.
138. Tsukamoto Y., Uchida T., Karnan S., Noguchi T., Nguyen L. T., Tanigawa M., Takeuchi I., Matsuura K., Hijiya N., Nakada C., Kishida T., Kawahara K., Ito H., Murakami K., Fujioka T., Seto M., Moriyama M. Genome-wide analysis of DNA copy number alterations and gene expression in gastric cancer. J. Pathol. 2008. 216, N 4. P. 471-482.
139. Jung S. H., Shin S. H., Yim S. H., Choi H. S., Lee S. H., Chung Y. J. Integrated analysis of copy number alteration and RNA expression profiles of cancer using a high-resolution whole-genome oligonucleotide array. Exp. Mol. Med. 2009. 41, N 7. P. 462-470.
140. Kadota M., Yang H. H., Gomez B., Sato M., Clifford R. J., Meerzaman D., Dunn B. K., Wakefield L. M., Lee M. P. Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. PLoS One. 2010. 5, N 2. e9201.
141. OrtizEstevez M., De Las Rivas J., Fontanillo C., Rubio A. Segmentation of genomic and transcriptomic microarrays data reveals major correlation between DNA copy number aberrations and gene-loci expression. Genomics. 2011. 97, N 2. P. 86-93.
142. Huang N., Shah P. K., Li C. Lessons from a decade of integrating cancer copy number alterations with gene expression profiles. Brief Bioinform. 2012. 13, N 3. P. 305-316
143. Geiger T., Cox J., Mann M. Proteomic changes resulting fromgene copy number variations in cancer cells. PLoS Genet. 2010. 6, N 9. e1001090.
144. Valsesia A., Rimoldi D., Martinet D., Ibberson M., Benaglio P., Quadroni M., Waridel P., Gaillard M., Pidoux M., Rapin B., Rivolta C., Xenarios I., Simpson A. J., Antonarakis S. E., Beckmann J. S., Jongeneel C. V., Iseli C., Stevenson B. J. Networkguided analysis of genes with altered somatic copy number and gene expression reveals pathways commonly perturbed in metastatic melanoma. PLoS One. 2011. 6, N 4. e18369.
145. Heng H. H., Liu G., Stevens J. B., Bremer S. W., Ye K. J., Ye C. J. Genetic and epigenetic heterogeneity in cancer: the ultimate challenge for drug therapy. Curr. Drug Targets. 2010. 11, N 10. P. 1304-1316.
146. Ye C. J., Stevens J. B., Liu G., Bremer S. W., Jaiswal A. S., Ye K. J., Lin M. F., Lawrenson L., Lancaster W. D., Kurkinen M., Liao J. D., Gairola C. G., Shekhar M. P., Narayan S., Miller F. R., Heng H. H. Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer. J. Cell Physiol. 2009. 219, N 2. P. 288-300.
147. Crespi B., Summers K. Evolutionary biology of cancer. Trends Ecol. Evol. 2005. 20, N 10. P. 545-552.
148. Greaves M. Darwinian medicine: a case for cancer. Nat. Rev. Cancer. 2007. 7, N 3. P. 213-221.
149. Marusyk A., DeGregori J. Declining cellular fitness with age promotes cancer initiation by selecting for adaptive oncogenic mutations. Biochim. Biophys. Acta. 2008. 1785, N 1. P. 1-11.
150. Merlo L. M., Wang L. S., Pepper J. W., Rabinovitch P. S., Maley C. C. Polyploidy, aneuploidy and the evolution of cancer. Adv. Exp. Med. Biol. 2010. 676. P. 1-13.
151. Vincent M. D. The animal within: carcinogenesis and the clonal evolution of cancer cells are speciation events sensu stricto. Evolution. 2010. 64, N 4. P. 1173-1183.
152. Vincent M. D. Cancer: beyond speciation. Adv. Cancer Res. 2011. 112. P. 283-350.
153. Gatenby R. A., Gillies R. J., Brown J. S. Of cancer and cave fish. Nat. Rev. Cancer. 2011. 11, N 4. P. 237-238.
154. Roychowdhury S., Talpaz M. Managing resistance in chronic myeloid leukemia. Blood Rev. 2011. 25, N 6. P. 279-290.
155. Rosenzweig S. A. Acquired resistance to drugs targeting receptor tyrosine kinases. Biochem. Pharmacol. 2011. 83, N 8. P. 1041-1048.
156. Palakurthi S., Yellepeddi V. K., Vangara K. K. Recent trends in cancer drug resistance reversal strategies using nanoparticles. Expert. Opin. Drug Deliv. 2012. 9, N 3. P. 287-301.
157. Pao W., Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer. 2010. 10, N 11. P. 760-774.
158. Mehra R., Serebriiskii I. G., Dunbrack R. L., Robinson M. K., Burtness B., Golemis E. A. Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family- targeted therapies in head and neck cancer. Drug Resist. Updat. 2011. 14, N 6. P. 260-279.
159. Carter C. A., Giaccone G. Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors. Curr. Opin. Oncol. 2012. 24, N 2. P. 123-129.
160. Brand T. M., Iida M., Wheeler D. L. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol. Ther. 2011. 11, N 9. P. 777-792.
161. Fiszman G. L., Jasnis M. A. Molecular mechanisms of trastuzumab resistance in HER2 overexpressing breast cancer. Int. J. Breast Cancer. 2011. Doi:10.4061/2011/352182.
162. Rezvani A. R., Maloney D. G. Rituximab resistance. Best. Pract. Res. Clin. Haematol. 2011. 24, N 2. P. 203-216.
163. Jazirehi A. R., Bonavida B. Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy. Methods Mol. Biol. 2011. 731. P. 407-419.
164. Garrett J. T., Arteaga C. L. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol. Ther. 2011. 11, N 9. P. 793-800.
165. Lovly C. M., Pao W. Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Sci. Transl. Med. 2012. 4, N 120. P. 120ps2.
166. Alcala A. M., Flaherty K. T. BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance. Clin. Cancer Res. 2012. 18, N 1. P. 33-39.
167. Little A. S., Balmanno K., Sale M. J., Smith P. D., Cook S. J. Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling. Biochem. Soc. Trans. 2012. 40, N 1. P. 73-78.
168. Hochhaus A., Kreil S., Corbin A. S., La Rosee P., Muller M. C., Lahaye T., Hanfstein B., Schoch C., Cross N. C., Berger U., Gschaidmeier H., Druker B. J., Hehlmann R. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002. 16, N 11. P. 2190-2196.
169. Kotchetkov R., Cinatl J., Blaheta R., Vogel J. U., Kaaskova J., Squire J., Hernaiz Driever P., Klingebiel T., Cinatl J. Jr. Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model. Int. J. Cancer. 2003. 104, N 1. P. 36-43.
170. Hu Y., Pang E., Lai P. B., Squire J. A., MacGregor P. F., Beheshti B., Albert M., Leung T. W., Wong N. Genetic alterations in doxorubicin-resistant hepatocellular carcinoma cells: a combined study of spectral karyotyping, positional expression profiling and candidate genes. Int. J. Oncol. 2004. 25, N 5. P. 1357-1364.
171. Pang E., Hu Y., Chan K. Y., Lai P. B., Squire J. A., Macgregor P. F., Beheshti B., Albert M., Leung T. W., Wong N. Karyotypic imbalances and differential gene expressions in the acquired doxorubicin resistance of hepatocellular carcinoma cells. Lab. Invest. 2005. 85, N 5. P. 664-674.
172. Swords R., Quinn J., Fay M., O’Donnell R., Goldman J., Murphy P. T. CML clonal evolution with resistance to single agent imatinib therapy. Clin. Lab. Haematol. 2005. 27, N 5. P. 347-349.
173. Zaccaria A., Valenti A. M., Donti E., Gozzetti A., Ronconi S., Spe- dicato F. Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia. Haematologica. 2007. 92, N 4. P. 564-565.
174. Rosenhahn J., Weise A., Michel S., Hennig K., Hartmann I., Schiefner J., Schubert K., Liehr T., von Eggeling F., Loncarevic I. F. Cytogenetic characterisation and proteomic profiling of the Imatinib-resistant cell line KCL22-R. Int. J. Oncol. 2007. 31, N 1. P. 121-128.
175. Whittington P. J., Piechocki M. P., Heng H. H., Jacob J. B., Jones R. F., Back J. B., Wei W. Z. DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies. Cancer Res. 2008. 68, N 18. P. 7502-7511.
176. Yamamoto K., Yakushijin K., Nishikawa S., Minagawa K., Katayama Y., Shimoyama M., Matsui T. Imatinib resistance in a novel translocation der(17)t(1;17)(q25;p13) with loss of TP53 but without BCR/ABL kinase domain mutation in chronic myelogenous leukemia. Cancer Genet. Cytogenet. 2008. 183, N 1. P. 77-81.
177. Dencic-Fekete M., Dordevic V., Storlazzi C.T., Jankovic G., Bogdanovic A., Jovanovic J., Rocchi M., Todoric-Zivanovic B., Strnad M., Gotic M. t(5;6;12) associated with resistance to imatinib mesylate in chronic myeloid leukemia. Int. J. Hematol. 2009. 89, N 4. P. 508-512.
178. Yuan J., Shah R., Kulharya A., Ustun C. Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to le-nalidomide and bortezomib in a multiple myeloma patient. Leuk. Res. 2010. 34, N 7. P. 954-957.
179. Hashemi J., Worrall C., Vasilcanu D., Fryknas M., Sulaiman L., Karimi M., Weng W. H., Lui W. O., Rudduck C., Axelson M., Jernberg-Wiklund H., Girnita L., Larsson O., Larsson C. Molecular characterization of acquired tolerance of tumor cells to picropo- dophyllin (PPP). PLoS One. 2011. 6, N 3. e14757.
180. Tegze B., Szallasi Z., Haltrich I., Penzvalto Z., Toth Z., Liko I., Gyorffy B. Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance. PLoS One. 2012. 7, N 2. e30804.
181. Michaelis M., Rothweiler F., Barth S., Cinatl J., van Rikxoort M., Loschmann N., Voges Y., Breitling R., von Deimling A., Rodel F., Weber K., Fehse B., Mack E., Stiewe T., Doerr H. W., Speidel D., Cinatl J.. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death Dis. 2011. 2. e243.
182. Kuramitsu Y., Taba K., Ryozawa S., Yoshida K., Zhang X., Tanaka T., Maehara S., Maehara Y., Sakaida I., Nakamura K. Identification of up- and down-regulated proteins in gemcitabine- resistant pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry. Anticancer Res. 2010. 30, N 9. P. 3367-3372.
183. Yoshida K., Kuramitsu Y., Murakami K., Ryozawa S., Taba K., Kaino S., Zhang X., Sakaida I., Nakamura K. Proteomic differential display analysis for TS-1-resistant and -sensitive pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry. Anticancer Res. 2011. 31, N 6. P. 2103-2108.
184. Chen Y. W., Liu J. Y., Lin S. T., Li J. M., Huang S. H., Chen J. Y., Wu J. Y., Kuo C. C., Wu C. L., Lu Y. C., Chen Y. H., Fan C. Y., Huang P. C., Law C. H., Lyu P. C., Chou H. C., Chan H. L. Proteomic analysis of gemcitabine-induced drug resistance in pancreatic cancer cells. Mol. Biosyst. 2011. 7, N 11. P. 3065-3074.
185. Ong P. S., Chan S. Y., Ho P. C. Microarray analysis revealed dysregulation of multiple genes associated with chemoresistance to As(2)O(3) and increased tumor aggressiveness in a newly established arsenic-resistant ovarian cancer cell line, OVCAR-3/AsR. Eur. J. Pharm. Sci. 2011. 45, N 3. P. 367-378.
186. Kars M. D., Iseri O. D., Gunduz U. A microarray based expression profiling of paclitaxel and vincristine resistant MCF-7 cells. Eur. J. Pharmacol. 2011. 657, N 1-3. P. 4-9.
187. Iseri O. D., Kars M. D., Arpaci F., Atalay C., Pak I., Gunduz U. Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern. Biomed. Pharmacother. 2011. 65, N 1. P. 40-45.
188. Iseri O. D., Kars M. D., Gunduz U. Two different docetaxel resistant MCF-7 sublines exhibited different gene expression pattern. Mol. Biol. Rep. 2012. 39, N 4. P. 3505-3516.
189. Mutlu P., Ural A. U., Gunduz U. Differential gene expressionanalysis related to extracellular matrix components in drug-resistant RPMI-8226 cell line. Biomed. Pharmacother. 2012. 66, N 3. P. 228-231.
190. Chen G., Bradford W. D., Seidel C. W., Li R. Hsp90 stress potentiates rapid cellular adaptation through induction of aneuploidy. Nature. 2012. 482, N 7384. P. 246-250.
191. Selmecki A. M., Dulmage K., Cowen L. E., Anderson J. B., Berman J. Acquisition of aneuploidy provides increased fitness during the evolution of antifungal drug resistance. PLoS Genet. 2009. 5, N 10. e1000705.
192. Ubeda J. M., Legare D., Raymond F., Ouameur A. A., Boisvert S., Rigault P., Corbeil J., Tremblay M. J., Olivier M., Papadopoulou B., Ouellette M. Modulation of gene expression in drug resistant Leishmania is associated with gene amplification, gene deletion and chromosome aneuploidy. Genome Biol. 2008. 9, N 7. R115.
193. Leprohon P., Legare D., Raymond F., Madore E., Hardiman G., Corbeil J., Ouellette M. Gene expression modulation is associated with gene amplification, supernumerary chromosomes and chromosome loss in antimony-resistant Leishmania infantum. Nucleic Acids Res. 2009. 37, N 5. P. 1387-1399.
194. Sionov E., Lee H., Chang Y. C., Kwon-Chung K. J. Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog. 2010. 6, N 4. e1000848.
195. Semighini C. P., Averette A. F., Perfect J. R., Heitman J. Deletion of Cryptococcus neoformans AIF ortholog promotes chromosome aneuploidy and fluconazole-resistance in a metacaspase- independent manner. PLoS Pathog. 2011. 7, N 11. e1002364.
196. Pavelka N., Rancati G., Li R. Dr Jekyll and Mr Hyde: role of aneuploidy in cellular adaptation and cancer. Curr. Opin. Cell. Biol. 2010. 22, N 6. P. 809-815.
197. Piras C., Soggiu A., Bonizzi L., Gaviraghi A., Deriu F., De Martino L., Iovane G., Amoresano A., Roncada P. Comparative proteomics to evaluate multi drug resistance in Escherichia coli. Mol. Biosyst. 2011. 8, N 4. P. 1060-1067.
198. Toprak E., Veres A., Michel J. B., Chait R., Hartl D. L., Kishony R. Evolutionary paths to antibiotic resistance under dynamically sustained drug selection. Nat. Genet. 2011. 44, N 1. P. 101-105.
199. Sass A., Marchbank A., Tullis E., Lipuma J. J., Mahenthiralingam E. Spontaneous and evolutionary changes in the antibiotic resistance of Burkholderia cenocepacia observed by global gene expression analysis. BMC Genomics. 2011. 12. P. 373.
200. Jackson M. A., Stack H. F., Waters M. D. Genetic activity profiles of anticancer drugs. Mutat. Res. 1996. 355, N 1-2. P. 171- 208.
201. Bonatti S., Simili M., Benedetti P. A., Morandi F., Menichini P., Del Carratore R., Barale R., Abbondandolo A. Altered centrosomes in ataxia-telangiectasia cells and rapamycin-treated Chinese hamster cells. Environ. Mol. Mutagen. 2005. 46, N 3. P. 164-173.
202. Fabarius A., Giehl M., Frank O., Spiess B., Zheng C., Muller M. C., Weiss C., Duesberg P., Hehlmann R., Hochhaus A., Seifarth W. Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability. Br. J. Haematol. 2007. 138, N 3. P. 369-373.
203. Fabarius A., Giehl M., Rebacz B., Kramer A., Frank O., Haferlach C., Duesberg P., Hehlmann R., Seifarth W., Hochhaus A. Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. Haematologica. 2008. 93, N 8. P. 1145-1154.
204. Goncalves E. M., Ventura C. A., Yano T., Rodrigues Macedo M. L., Genari S. C. Morphological and growth alterations in Vero cells transformed by cisplatin. Cell Biol. Int. 2006. 30, N 6. P. 485-494.
205. Bueno C., Catalina P., Melen G. J., Montes R., Sanchez L., Ligero G., Garcia-Perez J. L., Menendez P. Etoposide induces MLL rearrangements and other chromosomal abnormalities in human embryonic stem cells. Carcinogenesis. 2009. 30, N 9. P. 1628-1637.
206. Zacharaki P., Stephanou G., Demopoulos N. A. Comparison of the aneugenic properties of nocodazole, paclitaxel and griseofulvin in vitro. Centrosome defects and alterations in protein expression profiles. J. Appl. Toxicol. 2012. Doi: 10.1002/jat.2745.
207. Mujoo K., Zhang L., Klostergaard J., Donato N. J. Emergence of cisplatin-resistant cells from the OVCAR-3 ovarian carcinoma cell line with p53 mutations, altered tumorigenicity, and increased apoptotic sensitivity to p53 gene replacement. Int. J. Gynecol. Cancer. 2000. 10, N 2. P. 105-114.
208. Blaheta R. A., Daher F. H., Michaelis M., Hasenberg C., Weich E. M., Jonas D., Kotchetkov R., Doerr H. W., Cinatl J. Jr. Chemoresistance induces enhanced adhesion and transendothelial penetration of neuroblastoma cells by down-regulating NCAM surface expression. BMC Cancer. 2006. 6. P. 294.
209. LopezdeMesa R., LopezdeCerain Salsamendi A., Ariznabarreta L. S., Calasanz Abinzano M. J., Patino-Garcia A. Measurement and analysis of the chemotherapy-induced genetic instability in pediatric cancer patients. Mutagenesis. 2002. 17, N 2. P. 171-175.
210. Hijiya N., Hudson M. M., Lensing S., Zacher M., Onciu M., Behm F. G., Razzouk B. I., Ribeiro R. C., Rubnitz J. E., Sandlund J. T., Rivera G. K., Evans W. E., Relling M. V., Pui C. H. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA. 2007. 297, N 11. P. 1207-1215.
211. Meadows A. T., Friedman D. L., Neglia J. P., Mertens A. C., Donaldson S. S., Stovall M., Hammond S., Yasui Y., Inskip P. D. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J. Clin. Oncol. 2009. 27, N 14. P. 2356-2362.
212. Arnault J. P., Wechsler J., Escudier B., Spatz A., Tomasic G., Sibaud V., Aractingi S., Grange J. D., Poirier-Colame V., Malka D., Soria J. C., Mateus C., Robert C. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J. Clin. Oncol. 2009. 27, N 23. e59-61.
213. Witt K. L., Bishop J. B. Mutagenicity of anticancer drugs in mammalian germ cells. Mutat. Res. 1996. 355, N 1-2. P. 209-234.
214. Chandrakasan S., Ye C. J., Chitlur M., Mohamed A. N., Rabah R., Konski A., Heng H. H., Savagan S. Malignant fibrous histiocytoma two years after autologous stem cell transplant for Hodgkin lymphoma: evidence for genomic instability. Pediatr. Blood Cancer. 2011. 56, N 7. P. 1143-1145.
215. Glen C. D., Smith A. G., Dubrova Y. E. Single-molecule PCR analysis of germ line mutation induction by anticancer drugs in mice. Cancer Res. 2008. 68, N 10. P. 3630-3636.
216. Glen C. D., Dubrova Y. E. Exposure to anticancer drugs can result in transgenerational genomic instability in mice. Proc. Natl Acad. Sci. USA. 2012. 109, N 8. P. 2984-2988.
217. Correa D. D., Ahles T. A. Neurocognitive changes in cancer survivors. Cancer J. 2008. 14, N 6. P. 396-400.
218. Fardell J. E., Vardy J., Johnston I. N., Winocur G. Chemothe- rapy and cognitive impairment: treatment options. Clin. Pharmacol. Ther. 2011. 90, N 3. P. 366-376.
219. Janelsins M. C., Kohli S., Mohile S. G., Usuki K., Ahles T.A., Morrow G. R. An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Semin. Oncol. 2011. 38, N 3. P. 431-438.
220. Hartmann J. T., Haap M., Kopp H. G., Lipp H. P. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr. Drug Metab. 2009. 10, N 5. P. 470-481.
221. Amitay-Laish I., Stemmer S. M., Lacouture M. E. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol. Ther. 2011. 24, N 4. P. 386-395.
222. Min J. H., Lee H. Y., Lim H., Ahn M. J., Park K., Chung M. P., Lee K. S. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. Cancer Chemother. Pharmacol. 2011. 68, N 5. P. 1099-1109.
223. Blake-Haskins J. A., Lechleider R. J., Kreitman R. J. Thrombo- tic microangiopathy with targeted cancer agents. Clin. Cancer Res. 2011. 17, N 18. P. 5858-5866.
224. Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist. 2011. 16, Suppl. 2. P. 32-44.
225. Walraven M., Witteveen P. O., Lolkema M. P., van Hillegersberg R., Voest E. E., Verheul H. M. Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis. 2011. 14, N 2. P. 135-141.
226. Eschenhagen T., Force T., Ewer M. S., de Keulenaer G. W., Suter T. M., Anker S. D., Avkiran M., de Azambuja E., Balligand J. L., Brutsaert D. L., Condorelli G., Hansen A., Heymans S., Hill J. A., Hirsch E., Hilfiker-Kleiner D., Janssens S., de Jong S., Neubauer G., Pieske B., Ponikowski P., Pirmohamed M., Rauchhaus M., Sawyer D., Sugden P. H., Wojta J., Zannad F., Shah A.M. Cardiovascular side effects of cancer therapies: a position statement from the heart failure association of the european society of cardiology. Eur. J. Heart Fail. 2011. 13, N 1. P. 1-10.
227. Salie R., Silver R. T. Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia. Clin. Lymphoma Myeloma Leuk. 2010. 10, N 5. P. 331- 335.
228. Bonny M., Buyse V., Brochez L. Dermatological side effects of current and upcoming targeted therapies in oncology. Acta Clin. Belg. 2011. 66, N 2. P. 97-103.
229. Witteles R. M., Fowler M. B., Telli M. L. Chemotherapyassociated cardiotoxicity: how often does it really occur andhow can it be prevented?. Heart Fail Clin. 2011. 7, N 3. P. 333-344.
230. Grover S., Hill-Kayser C. E., Vachani C., Hampshire M. K., Dilullo G. A., Metz J. M. Patient reported late effects of gynecological cancer treatment. Gynecol. Oncol. 2012. 124, N 3. P. 399-403.
231. Gutzmer R., Wollenberg A., Ugurel S., Homey B., Ganser A., Kapp A. Cutaneous side effects of new antitumor drugs: clinical features and management. Dtsch. Arztebl. Int. 2012. 109, N 8. P. 133-140.
232. Hysing J., Wist E. Cardiotoxic effects of trastuzumab. Tidsskr. Nor. Laegeforen. 2011. 131, N 22. P. 2239-2241.
233. O’Regan K. N., Jagannathan J. P., Ramaiya N., Hodi F. S. Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy. AJR Am. J. Roentgenol. 2011. 197, N 2. W241-246.
234. Wolach O., Shpilberg O., Lahav M. Neutropenia after rituximab treatment: new insights on a late complication. Curr. Opin. Hematol. 2012. 19, N 1. P. 32-38.
235. Brambilla G., Mattioli F., Robbiano L., Martelli A. Update of carcinogenicity studies in animals and humans of 535 marketed pharmaceuticals. Mutat. Res. 2011. 197, N 2. P. 241-246.
236. Hail W. N. Forty years of translational cancer research. Cancer Discov. 2011. 1, N 5. P. 383-390.
237. Todorovic-Rakovic N. Genome-based versus gene-based theory of cancer: possible implications for clinical practice. J. Biosci. 2011. 36, N 4. P. 719-724.
238. Polyak K. Is breast tumor progression really linear?. Clin. Cancer Res. 2008. 14, N 2. P. 339-341.
239. Fox E. J., Beckman R. A., Loeb L. A. Reply: is there any genetic instability in human cancer?. DNA Repair (Amst). 2010. 9, N 8. P. 859-860.
240. Aktipis C. A., Kwan V. S., Johnson K. A., Neuberg S. L., Maley C. C. Overlooking evolution: a systematic analysis of cancer relapse and therapeutic resistance research. PLoS One. 2011. 6, N 11. e26100.
241. Longo D. L. Tumor heterogeneity and personalized medicine. N. Engl. J. Med. 2012. 366, N 10. P. 956-957.
242. Navin N., Hicks J. Future medical applications of single-cell sequencing in cancer. Genome Med. 2011. 3, N 5. P. 31.